Management of people with intermediate-stage hepatocellular carcinoma: An attempted network meta-analysis

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 3, 2017, Pages

  Roccarina, Davide ^a   Majumdar, Avik ^a   Thorburn, Douglas ^a   Davidson, Brian R ^b   Tsochatzis, Emmanuel ^a   Gurusamy, Kurinchi Selvan ^b  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE;

ABSENCE OF SIDE EFFECTS; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER REGISTRY; CANCER STAGING; CANCER THERAPY; CHEMOEMBOLIZATION; COMPARATIVE STUDY; FOLLOW UP; GENETIC HETEROGENEITY; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TRANSPLANTATION; LIVER WEIGHT; META ANALYSIS; PORTAL HYPERTENSION; PRIORITY JOURNAL; QUALITY OF LIFE; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; LIVER NEOPLASMS; MORTALITY; NETWORK META-ANALYSIS; PATHOLOGY; PROCEDURES; SEVERITY OF ILLNESS INDEX;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; HUMANS; LIVER NEOPLASMS; NETWORK META-ANALYSIS; NIACINAMIDE; PHENYLUREA COMPOUNDS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX;

EID: 85014858125     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD011649.pub2     Document Type: Review

References (183)

1. Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. Journal of hepatology 2012;57(4):821-9. [PUBMED: 22727733]5305364
2. Bruix J, Raoul JL, Sherman M, Shan M, Lentini G, Nadel A. Efficacy and safety of sorafenib in patients with hepatocellular carcinoma (HCC): subanalysis of sharp trial based on Barcelona clinic liver cancer (BCLC) stage. Journal of Hepatology 2009;50(Suppl 1):S28. 5305365
3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. New England Journal of Medicine 2008;359(4):378-90. 5305366
4. de Stefano G, Iodice V, Signoriello G, Scognamiglio U, Farella N. Efficacy and safety of combined sequential treatment with RFA and sorafenib in patients with HCC in intermediate stage ineligible for TACE: a prospective randomized open study. Journal of Hepatology 2015;62:S852-3. 5305368
5. de Stefano G, Scognamiglio U, Iodice V, Farella N, Simeone E, Montesarchio V. Efficacy and safety of combined sequential treatment with radiofrequency ablation and sorafenib in patients with hepatocellular carcinoma in intermediate stage ineligible for TACE: a prospective randomized open study. Annals of Oncology 2015;26:103-4. 5305369
6. Han G, Lencioni R, Llovet JM, Tak WY, Yang J, Guglielmi A, et al. Sorafenib plus transarterial chemoembolization with DC bead (DEB-TACE) for patients from Asian countries with intermediate-stage HCC: SPACE study results. Hepatology International 2013;7:S616. 5305371
7. Lencioni R, Llovet JM, Han G, Tak WY, Yang J, Guglielmi A, et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial. Journal of Hepatology 2016;64(5):1090-8. 5305372
8. Lencioni R, Zou J, Leberre M, Meinhardt G, Voliotis D, Bruix J, et al. Sorafenib (SOR) or placebo (PL) in combination with transarterial chemoembolization (TACE) for intermediate-stage hepatocellular carcinoma (SPACE). Journal of Clinical Oncology 2010;28(Suppl 15):26. 5305373
9. Abdelaziz AO, Nabeel MM, Elbaz TM, Shousha HI, Hassan EM, Mahmoud SH, et al. Microwave ablation versus transarterial chemoembolization in large hepatocellular carcinoma: prospective analysis. Scandinavian Journal of Gastroenterology 2015;50(4):479-84. 5305375
10. Anonymous . A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d'etude et de traitement du carcinome hepatocellulaire. New England Journal of Medicine 1995;332(19):1256-61. 5305377
11. Arai Y, Inaba Y, Yamamoto T, Kanai F, Aramaki T, Tanaka T, et al. A randomized phase II study of TSU-68 in patients (pts) with hepatocellular carcinoma (HCC) treated by transarterial chemoembolization (TACE). Journal of Clinical Oncology Conference 2010;28(15 Suppl 1):Abstract: 4030. 5305379
12. Bartolozzi C, Lencioni R, Caramella D, Vignali C, Cioni R, Mazzeo S, et al. Treatment of large HCC: transcatheter arterial chemoembolization combined with percutaneous ethanol injection versus repeated transcatheter arterial chemoembolization. Radiology 1995;197(3):812-8. 5305381
13. Becker G, Soezgen T, Olschewski M, Laubenberger J, Blum HE, Allgaier HP. Combined TACE and PEI for palliative treatment of unresectable hepatocellular carcinoma. World Journal of Gastroenterology 2005;11(39):6104-9. 5305383
14. Bruix J, Llovet JM, Castells A, Montana X, Bru C, Ayuso MC, et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology (Baltimore, Md.) 1998;27(6):1578-83. 5305385
15. Chen MS, Li JQ, Zhang YQ, Lu LX, Zhang WZ, Yuan YF, et al. High-dose iodized oil transcatheter arterial chemoembolization for patients with large hepatocellular carcinoma. World Journal of Gastroenterology 2002;8(1):74-8. 5305387
16. Chen XP, Hu DY, Zhang ZW, Zhang BX, Chen YF, Zhang WG, et al. Role of mesohepatectomy with or without transcatheter arterial chemoembolization for large centrally located hepatocellular carcinoma. Digestive Surgery 2007;24(3):208-13. 5305389
17. Cheng SQ, Wu MC, Chen H, Shen F, Yang JH, Cong WM, et al. Transcatheter hepatic arterial chemoembolization and thymosin alpha1 in postoperative treatment of hepatocellular carcinoma. Zhonghua Zhong Liu Za Zhi 2004;26(5):305-7. 5305391
18. Cheng BQ, Jia CQ, Liu CT, Fan W, Wang QL, Zhang ZL, et al. Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial. (Retraction in: JAMA 2009; 301(18):1931). JAMA 2008;299(14):1669-77. 5305393
19. Choi C, Koom WS, Kim TH, Yoon SM, Kim JH, Lee HS, et al. A prospective phase 2 multicenter study for the efficacy of radiation therapy following incomplete transarterial chemoembolization in unresectable hepatocellular carcinoma. International Journal of Radiation Oncology 2014;90(5):1051-60. 5305395
20. Chow PK, Tai BC, Tan CK, Machin D, Win KM, Johnson PJ, et al. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomized controlled trial. Hepatology (Baltimore, Md.) 2002;36(5):1221-6. 5305397
21. DeAngelis CD, Fontanarosa PB. Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial. (Retraction of: JAMA 2008; 299(14):1669-77). JAMA 2009;301(18):1931. 5305399
22. Doffoel M, Bonnetain F, Bouche O, Vetter D, Abergel A, Fratte S, et al. Multicentre randomised phase III trial comparing tamoxifen alone or with transarterial lipiodol chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients. European Journal of Cancer 2008;44(4):528-38. 5305401
23. El-Kady NM, Esmat G, Mahmoud EH, Darweesh SK, Mahmoud SH, Elagawy WA. Hypertonic saline-enhanced radiofrequency versus chemoembolization sequential radiofrequency in the treatment of large hepatocellular carcinoma. European Journal of Gastroenterology & Hepatology 2013;25(5):628-33. 5305403
24. Ferrari FS, Stella A, Gambacorta D, Magnolfi F, Fantozzi F, Pasquinucci P, et al. Treatment of large hepatocellular carcinoma: comparison between techniques and long term results. Radiologia Medica 2004;108(4):356-71. 5305405
25. Fischman AM, Lewis SC, Patel R, Kim E, Nowakowski FS, Lookstein RA, et al. Prospective, randomized study of coiling vs surefire infusion system in Y-90: clinical outcomes in HCC patients-subgroup analysis of safety and efficacy from the COSY trial. Cardiovascular and Interventional Radiology 2014;37(2 Suppl 1):S252. 5305407
26. Gallo C, De Maio E, Di Maio M, Signoriello G, Daniele B, Pignata S, et al. Tamoxifen is not effective in good prognosis patients with hepatocellular carcinoma. BMC Cancer 2006;6:196. 5305409
27. Gish RG, Gordon SC, Nelson D, Rustgi V, Rios I. A randomized controlled trial of thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinoma. Hepatology International 2009;3(3):480-9. 5305411
28. Golfieri R, Giampalma E, Renzulli M, Cioni R, Bargellini I, Bartolozzi C, et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. British Journal of Cancer 2014;111(2):255-64. 5305413
29. Hebbar M, Heurgue-Berlot A, Boige V, Malicot K, Bernard-Chabert B, Marcus C, et al. Randomized phase 2/3 trial of transcatheter arterial chemoembolization (TACE) plus sunitinib or placebo in patients with hepatocellular carcinoma (HCC) (PRODIGE 16/SATURNE study): results of the phase II part. European Journal of Cancer 2015;51:S434. 5305415
30. Hilgard P, Trojan J, Galle PR, Greten T, Erhardt A, Shan M, et al. Sorafenib improves survival in patients with hepatocellular carcinoma: results of a large multicenter, randomized, placebo-controlled phase III trial. Onkologie 2008;31(Suppl 1):78. 5305417
31. Hou YB, Chen MH, Yan K, Wu JY, Yang W. Adjuvant percutaneous radiofrequency ablation of feeding artery of hepatocellular carcinoma before treatment. World Journal of Gastroenterology 2009;15(21):2638-43. 5305419
32. Huo TI, Huang YH, Wu JC, Lee PC, Chang FY, Lee SD. Comparison of percutaneous acetic acid injection and percutaneous ethanol injection for hepatocellular carcinoma in cirrhotic patients: a prospective study. Scandinavian Journal of Gastroenterology 2003;38(7):770-8. 5305421
33. Iezzi R, Cesario V, Siciliani L, Campanale M, De Gaetano AM, Siciliano M, et al. Single-step multimodal locoregional treatment for unresectable hepatocellular carcinoma: balloon-occluded percutaneous radiofrequency thermal ablation (BO-RFA) plus transcatheter arterial chemoembolization (TACE). Radiologia Medica 2013;118(4):555-69. 5305423
34. Inaba Y, Kanai F, Aramaki T, Yamamoto T, Tanaka T, Yamakado K, et al. A randomised phase II study of TSU-68 in patients with hepatocellular carcinoma treated by transarterial chemoembolisation. European Journal of Cancer 2013;49(13):2832-40. 5305425
35. Kaneko S, Inaba Y, Kanai F, Aramaki T, Yamamoto T, Tanaka T, et al. Final results of a randomized phase II study of TSU-68 after transarterial chemoembolisation in Japanese patients with unresectable hepatocellular carcinoma. Annals of Oncology 2012;23:ix243. 5305426
36. Kolligs FT, Bilbao JI, Jakobs T, Inarrairaegui M, Nagel JM, Rodriguez M, et al. Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma. Liver International 2015;35(6):1715-21. 5305428
37. Kudo M, Chung H, Ogawa C, Fukuda N, Suetomi Y, Minami Y, et al. Radiofrequency ablation therapy combined with or without subsegmental lipiodol TAE for large hepatocellular carcinoma: a randomized prospective study. Hepatology (Baltimore, Md.) 2002;36(4):693A-4A. 5305430
38. Kudo M, Han G, Finn RS, Poon RT, Blanc JF, Yan L, et al. Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized phase III trial. Hepatology (Baltimore, Md.) 2014;60(5):1697-707. 5305432
39. Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovascular and Interventional Radiology 2010;33(1):41-52. 5305434
40. Li CX, Wu PH, Fan WJ, Huang JH, Zhang FJ, Zhang L, et al. Clinical effect of transcatheter arterial chemoembolization combined with high intensity focused ultrasound ablation in treatment of large hepatocellular carcinoma. National Medical Journal of China 2009;89(11):754-7. 5305436
41. Li CX, Zhang WD, Zhang R, Zhang LA, Wu PH, Zhang FJ. Therapeutic effects and prognostic factors in high-intensity focused ultrasound combined with chemoembolisation for larger hepatocellular carcinoma. European Journal of Cancer 2010;46(13):2513-21. 5305438
42. Liu FY, Yu XL, Liang P, Wang Y, Zhou P, Yu J. Comparison of percutaneous 915 MHz microwave ablation and 2450 MHz microwave ablation in large hepatocellular carcinoma. International Journal of Hyperthermia 2010;26(5):448-55. 5305440
43. Livraghi T, Meloni F, Frosi A, Lazzaroni S, Bizzarri M, Frati L, et al. Treatment with stem cell differentiation stage factors of intermediate-advanced hepatocellular carcinoma: an open randomized clinical trial. Oncology Research 2005;15(7-8):399-408. 5305442
44. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359(9319):1734-9. 5305444
45. Llovet J, Mazzaferro V, Ricci S, Hilgard P, Raoul J, Zeuzem S, et al. Sorafenib improves survival in a large multi-center, randomized, placebo-controlled phase III trial in patients with hepatocellular carcinoma. European Journal of Cancer 2007;5(4 Suppl):261. 5305446
46. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology (Baltimore, Md.) 2002;35(5):1164-71. 5305448
47. Malagari K, Pomoni M, Kelekis A, Pomoni A, Dourakis S, Spyridopoulos T, et al. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with beadblock for hepatocellular carcinoma. Cardiovascular and Interventional Radiology 2010;33(3):541-51. 5305450
48. Meyer T, Fox R, Ma YT, Ross PJ, James M, Strugess R, et al. TACE 2: a randomized placebo-controlled, double-blinded, phase III trial evaluating sorafenib in combination with transarterial chemoembolisation (TACE) in patients with unresectable hepatocellular carcinoma (HCC). Journal of Clinical Oncology Conference 2016;34:Abstract: 4018. 5305452
49. Mohnike K, Pech M, Seidensticker M, Seidensticker R, Bretschneider T, Schuette K, et al. A prospective randomized trial comparing HDR-brachytherapy and transarterial chemoembolization in hepatocellular carcinoma. Journal of Hepatology 2013;58:S50. 5305454
50. Morimoto M, Numata K, Kondou M, Nozaki A, Morita S, Tanaka K. Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. Cancer 2010;116(23):5452-60. 5305456
51. Morimoto M, Numata K, Kondo M, Nozaki A, Moriya S, Takizawa K. Long-term outcome in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial to determine the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. Hepatology (Baltimore, Md.) 2011;54(4 Suppl):1366A-7A. 5305458
52. Okusaka T, Kasugai H, Ishii H, Kudo M, Sata M, Tanaka K, et al. A randomized phase II trial of intra-arterial chemotherapy using SM-11355 (miriplatin) for hepatocellular carcinoma. Investigational New Drugs 2012;30(5):2015-25. 5305460
53. Padia SA, Shivaram G, Bastawrous S, Bhargava P, Vo NJ, Vaidya S, et al. Safety and efficacy of drug-eluting bead chemoembolization for hepatocellular carcinoma: comparison of small-versus medium-size particles. Journal of Vascular & Interventional Radiology 2013;24(3):301-6. 5305462
54. Pelletier G, Ducreux M, Gay F, Luboinski M, Hagege H, Dao T, et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. Journal of Hepatology 1998;29(1):129-34. 5305464
55. Sansonno D, Lauletta G, Russi S, Conteduca V, Sansonno L, Dammacco F. Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial. Oncologist 2012;17(3):359-66. 5305466
56. Sarin SK, Sreenivas DV, Saraya A, Mehta S, Lahoti D, Malhotra V. Improved survival with percutaneous ethanol injection in patients with large hepatocellular carcinoma. European Journal of Gastroenterology and Hepatology 1994;6(11):999-1003. 5305468
57. Shi M, Chen J, Lin X, Chen M, Guo R, Li S, et al. Prospective randomized controlled study of transarterial chemoembolization with doxorubicin versus doxorubicin/lobaplatin/mitomycin combination for unresectable hepatocellular carcinoma. Chinese Journal of Clinical Oncology 2009;36(1):9-12. 5305470
58. Tanaka M, Ando E, Simose S, Hori M, Kuraoka K, Ohno M, et al. Radiofrequency ablation combined with transarterial chemoembolization for intermediate hepatocellular carcinoma. Hepatology Research 2014;44(2):194-200. 5305472
59. Tang QH, Zhou JP, Fu SY, Zhou WP. Effect of preoperative transcatheter arterial chemoembolization for treatment of resectable large hepatocellular carcinoma: a clinical randomized controlled trial. Academic Journal of Second Military Medical University 2009;30(12):1379-84. 5305474
60. Ulbrich G, Kolblinger C, Pinter M, Reiberger T, Ferlitsch A, Sieghart W, et al. AVATACE-1 trial: bevacizumab as inhibitor of collateral tumor-vessel-growth during transarterial chemoembolisation (TACE) for hepatocellular carcinoma - a double-blind, randomized, placebo-controlled pilot-trial. Hepatology (Baltimore, Md.) 2010;52:1159A-60A. 5305476
61. Ulbrich G, Pinter M, Reiberger T, Ferlitsch A, Sieghart W, Peck-Radosavljevic M. Interim safety-analysis of the AVATACE-1 trial (bevacizumab as inhibitor of collateral tumor-vessel-growth during transarterial chemoembolisation (TACE) for hepatocellular carcinoma - a double-blind randomized placebo-controlled pilot-trial. Journal of Hepatology 2010;52:S54. 5305478
62. Wang YB, Chen MH, Yan K, Yang W, Dai Y, Yin SS. Quality of life after radiofrequency ablation combined with transcatheter arterial chemoembolization for hepatocellular carcinoma: comparison with transcatheter arterial chemoembolization alone. Quality of Life Research 2007;16(3):389-97. 5305480
63. Wang LJ, Bu WZ, Chen H, Li JP, Ma SS, Song JL. Clinical study of TACE with or without antiviral treatment for hepatitis B virus related unresectable hepatocellular carcinoma. Chinese Journal of Cancer Prevention and Treatment 2014;21(20):1617-22. 5305482
64. Wu CC, Ho YZ, Ho WL, Wu TC, Liu TJ, P'Eng FK. Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma: a reappraisal. British Journal of Surgery 1995;82(1):122-6. 5305484
65. Wu P, Li L, Zhang Y. Transcatheter arterial chemo-embolization combined with CT-guided percutaneous intratumoral injection of lipiodol-ethanol for the treatment of primary hepatocellular carcinoma. Zhonghua Zhong Liu za Zhi [Chinese Journal of Oncology] 1998;20(5):391-3. 5305486
66. Xie ZR, Luo YL, Xiao FM, Liu Q, Ma Y. Health-related quality of life of patients with intermediate hepatocellular carcinoma after liver resection or transcatheter arterial chemoembolization. Asian Pacific Journal of Cancer Prevention 2015;16(10):4451-6. 5305488
67. Xu KC, Niu LZ, Zhou Q, Hu YZ, Guo DH, Liu ZP, et al. Sequential use of transarterial chemoembolization and percutaneous cryosurgery for hepatocellular carcinoma. World Journal of Gastroenterology 2009;15(29):3664-9. 5305490
68. Yang P, Liang M, Zhang Y, Shen B. Clinical application of a combination therapy of lentinan, multi-electrode RFA and TACE in HCC. Advances in Therapy 2008;25(8):787-94. 5305492
69. Yin L. A prospective RCT comparing partial hepatectomy with TACE for multinodular HCC outside of Milan criteria. HPB : the Official Journal of the International Hepato Pancreato Biliary Association 2013;15:21-2. 5305494
70. Zhang Q, Chen H, Li Q, Zang YJ, Chen XG, Zou WL, et al. Combination adjuvant chemotherapy with oxaliplatin, 5-fluorouracil and leucovorin after liver transplantation for hepatocellular carcinoma: a preliminary open-label study. Investigational New Drugs 2011;29(6):1360-9. 5305496
71. Zhou WP, Lai EC, Li AJ, Fu SY, Zhou JP, Pan ZY, et al. A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma. Annals of Surgery 2009;249(2):195-202. 5305498
72. Lee KG, Kyung T. A study of MG4101 (allogeneic natural killer cell) for intermediate-stage of hepatocellular carcinoma. clinicaltrials.gov/ct2/show/NCT02854839 Date first received: 2016. 5305500
73. Seinstra BA, Defreyne L, Lambert B, Lam M, Verkooijen HM, van Erpecum KJ, et al. Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (trace): study protocol for a randomized controlled trial. Trials 2012;13:144. 5305502
74. Seinstra BA, Defreyne L, Lambert B, Lam M, Verkooijen L, Van Erpecum KJ, et al. Transarterial radioembolization versus chemoembolization for the treatment of HCC: trace trial-an international multicenter randomized controlled trial. Journal of Vascular and Interventional Radiology 2012;23(3 Suppl):S150-1. 5305503
75. Arnaoutakis DJ, Mavros MN, Shen F, Alexandrescu S, Firoozmand A, Popescu I, et al. Recurrence patterns and prognostic factors in patients with hepatocellular carcinoma in noncirrhotic liver: a multi-institutional analysis. Annals of Surgical Oncology 2014;21(1):147-54.
76. Asham EH, Kaseb A, Ghobrial RM. Management of hepatocellular carcinoma. Surgical Clinics of North America 2013;93(6):1423-50.
77. Bosetti C, Turati F, La Vecchia C. Hepatocellular carcinoma epidemiology. Best Practice & Research: Clinical Gastroenterology 2014;28(5):753-70.
78. Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.) 2011;53(3):1020-2.
79. Chaimani A, Salanti G. Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions. Research Synthesis Methods 2012;3(2):161-76.
80. Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-analysis in STATA. PloS one 2013;8(10):e76654.
81. Chan AC, Cheung TT, Fan ST, Chok KS, Chan SC, Poon RT, et al. Survival analysis of high-intensity focused ultrasound therapy versus radiofrequency ablation in the treatment of recurrent hepatocellular carcinoma. Annals of Surgery 2013;257(4):686-92.
82. Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al. Spirit 2013 statement: defining standard protocol items for clinical trials. Annals of Internal Medicine 2013;158(3):200-7.
83. Chen Y, Wang X, Wang J, Yan Z, Luo J. Excess body weight and the risk of primary liver cancer: an updated meta-analysis of prospective studies. European Journal of Cancer 2012;48(14):2137-45.
84. Cillo U, Vitale A, Grigoletto F, Farinati F, Brolese A, Zanus G, et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system. Journal of Hepatology 2006;44(4):723-31.
85. The cancer of the liver Italian program (CLIP) investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998;28(3):751-5.
86. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 2004;127(5):1372-80.
87. Del Re AC, Spielmans GI, Flückiger C, Wampold BE. Efficacy of new generation antidepressants: differences seem illusory. PLoS One 2013;8(6):e63509.
88. DeMets DL. Methods for combining randomized clinical trials: strengths and limitations. Statistics in Medicine 1987;6(3):341-50.
89. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88.
90. Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. Statistics in Medicine 2010;29(7-8):932-44.
91. Dias S, Sutton AJ, Welton NJ, Ades AE. NICE DSU Technical Support Document 3: heterogeneity: subgroups, meta-regression, bias and bias-adjustment, September 2011 (last updated April 2012). www.nicedsu.org.uk/TSD3%20Heterogeneity.final%20report.08.05.12.pdf (accessed 27 March 2014).
92. Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU Technical Support Document 1: introduction to evidence synthesis for decision making, April 2011 (last updated April 2012). www.nicedsu.org.uk/TSD1%20Introduction.final.08.05.12.pdf (accessed 27 March 2014).
93. Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU Technical Support Document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials, August 2011 (last updated April 2014). www.nicedsu.org.uk/TSD2%20General%20meta%20analysis%20corrected%2015April2014.pdf (accessed 8 October 2014).
94. Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE. NICE DSU Technical Support Document 4: inconsistency in networks of evidence based on randomised controlled trials, May 2011 (last updated April 2014). www.nicedsu.org.uk/TSD4%20Inconsistency.final.15April2014.pdf (accessed 8 October 2014).
95. European Association for Study of Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Journal of Hepatology 2012;56(4):908-43.
96. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical Research Ed.) 1997;315(7109):629-34.
97. EuroQol . About EQ-5D, 2014. www.euroqol.org/about-eq-5d.html (accessed 8 October 2014).
98. Forner A, Gilabert M, Bruix J, Raoul JL. Treatment of intermediate-stage hepatocellular carcinoma. Nature Reviews: Clinical Oncology 2014;11(9):525-35.
99. Gaddikeri S, McNeeley MF, Wang CL, Bhargava P, Dighe MK, Yeh MMC, et al. Hepatocellular carcinoma in the noncirrhotic liver. American Journal of Roentgenology 2014;203(1):W34-47.
100. Germani G, Pleguezuelo M, Gurusamy K, Meyer T, Isgro G, Burroughs AK. Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocellular carcinoma: a meta-analysis. Journal of Hepatology 2010;52(3):380-8.
101. Germani G, Gurusamy K, Garcovich M, Toso C, Fede G, Hemming A, et al. Which matters most: number of tumors, size of the largest tumor, or total tumor volume?. Liver Transplantation 2011;17(Suppl 2):S58-66.
102. Gluud C, Nikolova D, Klingenberg SL. Cochrane Hepato-Biliary Group. About Cochrane (Cochrane Review Groups (CRGs)) 2016, Issue 10. Art. No.: LIVER.
103. Guglielmi A, Ruzzenente A, Conci S, Valdegamberi A, Vitali M, Bertuzzo F, et al. Hepatocellular carcinoma: surgical perspectives beyond the Barcelona Clinic Liver Cancer recommendations. World Journal of Gastroenterology 2014;20(24):7525-33.
104. Gurusamy KS, Nagendran M, Davidson BR. Methods of preventing bacterial sepsis and wound complications after liver transplantation. Cochrane Database of Systematic Reviews 2014, Issue 3. [DOI: 10.1002/14651858.CD006660.pub3]
105. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383-94.
106. Head HW, Dodd GD, 3rd . Thermal ablation for hepatocellular carcinoma. Gastroenterology 2004;127(5 Suppl 1):S167-78.
107. Henderson JM, Sherman M, Tavill A, Abecassis M, Chejfec G, Gramlich T. AHPBA/AJCC consensus conference on staging of hepatocellular carcinoma: consensus statement. HPB : the Official Journal of the International Hepato Pancreato Biliary Association 2003;5(4):243-50.
108. Higgins JPT, Green S, editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
109. Higgins JPT, Jackson D, Barrett JK, Lu G, Ades AE, White IR. Consistency and inconsistency in network meta-analysis: Concepts and models for multi-arm studies. Research Synthesis Methods 2012;3(2):98-110.
110. Hoffmann R, Rempp H, Syha R, Ketelsen D, Pereira PL, Claussen CD, et al. Transarterial chemoembolization using drug eluting beads and subsequent percutaneous MR-guided radiofrequency ablation in the therapy of intermediate sized hepatocellular carcinoma. European Journal of Radiology 2014;83(10):1793-8.
111. International Agency for Research on Cancer. GLOBOCAN 2012: estimated cancer incidence, mortality, and prevalence worldwide in 2012. Liver cancer estimated incidence, mortality and prevalence worldwide in 2012. globocan.iarc.fr/Pages/fact_sheets_cancer.aspx (accessed 17 October 2014).
112. International Agency for Research on Cancer. World 2012 (estimated cancer incidence, all ages: both sexes). globocan.iarc.fr/old/summary_table_pop-html.asp?selection=224900&title=World&sex=0&type=0&window=1&sort=0&submit=%C2%A0Execute (accessed 17 October 2014).
113. International Conference on Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice CFR & ICH Guidelines. Vol. 1, Philadelphia (PA): Barnett International/PAREXEL, 1997.
114. Jakobsen JC, Wetterslev J, Winkel P, Lange T, Gluud C. Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology 2014;14(1):120.
115. Jepsen P, Vilstrup H, Tarone RE, Friis S, Sorensen HT. Incidence rates of hepatocellular carcinoma in the U.S. and Denmark: recent trends. International Journal of Cancer 2007;121(7):1624-6.
116. Kansagara D, Papak J, Pasha AS, O'Neil M, Freeman M, Relevo R, et al. Screening for hepatocellular carcinoma in chronic liver disease: a systematic review. Annals of Internal Medicine 2014;161(4):261-9.
117. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine 2001;135(11):982-9.
118. Kollar L, Rengan R. Stereotactic body radiotherapy. Seminars in Oncology 2014;41(6):776-89.
119. Ladep NG, Khan SA, Crossey MM, Thillainayagam AV, Taylor-Robinson SD, Toledano MB. Incidence and mortality of primary liver cancer in England and Wales: changing patterns and ethnic variations. World Journal of Gastroenterology 2014;20(6):1544-53.
120. Lee YC, Cohet C, Yang YC, Stayner L, Hashibe M, Straif K. Meta-analysis of epidemiologic studies on cigarette smoking and liver cancer. International Journal of Epidemiology 2009;38(6):1497-511.
121. Lencioni R, Petruzzi P, Crocetti L. Chemoembolization of hepatocellular carcinoma. Seminars in Interventional Radiology 2013;30(1):3-11.
122. Liu Y, Chang CC, Marsh GM, Wu F. Population attributable risk of aflatoxin-related liver cancer: systematic review and meta-analysis. European Journal of Cancer 2012;48(14):2125-36.
123. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Seminars in Liver Disease 1999;19(3):329-38.
124. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362(9399):1907-17.
125. Lu G, Ades AE. Assessing evidence inconsistency in mixed treatment comparisons. Journal of the American Statistical Association 2006;101(474):447-59.
126. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews 2017, Issue 2. [DOI: 10.1002/14651858.MR000033.pub3]
127. Macaskill P, Walter SD, Irwig L. A comparison of methods to detect publication bias in meta-analysis. Statistics in Medicine 2001;20(4):641-54.
128. Maheshwari S, Sarraj A, Kramer J, El-Serag HB. Oral contraception and the risk of hepatocellular carcinoma. Journal of Hepatology 2007;47(4):506-13.
129. Majumdar A, Roccarina D, Thorburn D, Davidson BR, Tsochatzis E, Gurusamy KS. Management of people with early or very early stage hepatocellular carcinoma: a network meta-analysis. Cochrane Database of Systematic Reviews 2017, Issue In editorial. [DOI: 10.1002/14651858.CD011650]
130. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. New England Journal of Medicine 1996;334(11):693-9.
131. McDermott S, Gervais DA. Radiofrequency ablation of liver tumors. Seminars in Interventional Radiology 2013;30(1):49-55.
132. Miladinovic J, Hozo I, Djulbegovic B. Trial sequential boundaries for cumulative meta-analyses. Stata Journal 2013;13(1):77-91.
133. Mills EJ, Ioannidis JP, Thorlund K, Schünemann HJ, Puhan MA, Guyatt GH. How to use an article reporting a multiple treatment comparison meta-analysis. JAMA 2012;308(12):1246-53.
134. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352(9128):609-13.
135. Nanashima A, Sumida Y, Abo T, Shindou H, Fukuoka H, Takeshita H, et al. Modified Japan Integrated Staging is currently the best available staging system for hepatocellular carcinoma patients who have undergone hepatectomy. Journal of Gastroenterology 2006;41(3):250-6.
136. NCBI . Carcinoma, hepatocellular, 2014. www.ncbi.nlm.nih.gov/mesh/68006528 (accessed 17 October 2014).
137. Newell DJ. Intention-to-treat analysis: implications for quantitative and qualitative research. International Journal of Epidemiology 1992;21(5):837-41.
138. Nguyen KT, Gamblin TC, Geller DA. World review of laparoscopic liver resection - 2, 804 patients. Annals of Surgery 2009;250(5):831-41.
139. NHS Blood and Transplant. Organ donation. Activity report 2013-2014. www.organdonation.nhs.uk/statistics/transplant_activity_report/ (accessed 8 October 2014).
140. Niu M, Hong D, Ma TC, Chen XW, Han JH, Sun J, et al. Short-term and long-term efficacy of 7 targeted therapies for the treatment of advanced hepatocellular carcinoma: a network meta-analysis: Efficacy of 7 targeted therapies for AHCC. Medicine 2016;95(49):e5591.
141. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985;56(4):918-28. [PUBMED: 2990661]
142. Oliveri RS, Wetterslev J, Gluud C. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database of Systematic Reviews 2011, Issue 3. [DOI: 10.1002/14651858.CD004787.pub2]
143. Members of OpenBUGS Project Management Group. OpenBUGS. Version 3.2.3. Members of OpenBUGS Project Management Group, 2014.
144. Organ Procurement and Transplantation Network. Policies, 2014. optn.transplant.hrsa.gov/ContentDocuments/OPTN_Policies.pdf (accessed on 17 October 2014).
145. Pleguezuelo M, Marelli L, Misseri M, Germani G, Calvaruso V, Xiruochakis E, et al. TACE versus TAE as therapy for hepatocellular carcinoma. Expert Review of Anticancer Therapy 2008;8(10):1623-41.
146. Pocobelli G, Cook LS, Brant R, Lee SS. Hepatocellular carcinoma incidence trends in Canada: analysis by birth cohort and period of diagnosis. Liver International 2008;28(9):1272-9.
147. Polesel J, Zucchetto A, Montella M, Dal Maso L, Crispo A, La Vecchia C, et al. The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma. Annals of Oncology 2009;20(2):353-7.
148. Prasad KR, Young RS, Burra P, Zheng SS, Mazzaferro V, Moon DB, et al. Summary of candidate selection and expanded criteria for liver transplantation for hepatocellular carcinoma: a review and consensus statement. Liver Transplantation 2011;17(Suppl 2):S81-9.
149. Puhan MA, Schünemann HJ, Murad MH, Li T, Brignardello-Petersen R, Singh JA, et al. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ (Clinical Research Ed.) 2014;349:g5630.
150. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
151. Royle P, Milne R. Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care 2003;19(4):591-603.
152. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. Journal of Clinical Epidemiology 2011;64(2):163-71.
153. Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Research Synthesis Methods 2012;3(2):80-97.
154. Sang LX, Chang B, Li XH, Jiang M. Consumption of coffee associated with reduced risk of liver cancer: a meta-analysis. BMC Gastroenterology 2013;13:34.
155. Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized controlled trials: combined analysis of meta-epidemiological studies. Health Technology Assessment 2012;16(35):1-82.
156. Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized controlled trials. Annals of Internal Medicine 2012;157(6):429-38.
157. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12.
158. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. PLoS Medicine 2010;7(3):e1000251.
159. Severini TA. Bayesian interval estimates which are also confidence intervals. Journal of the Royal Statistical Society. Series B (Methodological) 1993;55(2):533-40.
160. Sindram D, Lau KN, Martinie JB, Iannitti DA. Hepatic tumor ablation. Surgical Clinics of North America 2010;90(4):863-76.
161. Scientific Registry of Transplant Recipients. OPTN/SRTR 2012 annual data report: liver. srtr.transplant.hrsa.gov/annual_reports/2012/pdf/03_liver_13.pdf (accessed 8 October 2014).
162. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology (Baltimore, Md.) 2010;51(5):1820-32.
163. StataCorp LP. Stata/SE 14.2 for Windows[64-bit x86-64]. Version 14. College Station: StataCorp LP, 2017.
164. Taura N, Yatsuhashi H, Nakao K, Ichikawa T, Ishibashi H. Long-term trends of the incidence of hepatocellular carcinoma in the Nagasaki prefecture, Japan. Oncology Reports 2009;21(1):223-7.
165. Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C. User manual for Trial Sequential Analysis (TSA). ctu.dk/tsa/files/tsa_manual.pdf 2011 (accessed 29 November 2016).
166. Thorlund K, Mills EJ. Sample size and power considerations in network meta-analysis. Systematic Reviews 2012;1:41.
167. Copenhagen Trial Unit. TSA - Trial Sequential Analysis. Version 0.9 Beta. Copenhagen: Copenhagen Trial Unit, 2011.
168. Tsochatzis EA, Fatourou E, O'Beirne J, Meyer T, Burroughs AK. Transarterial chemoembolization and bland embolization for hepatocellular carcinoma. World Journal of Gastroenterology 2014;20(12):3069-77.
169. Turati F, Edefonti V, Talamini R, Ferraroni M, Malvezzi M, Bravi F, et al. Family history of liver cancer and hepatocellular carcinoma. Hepatology (Baltimore, Md.) 2012;55(5):1416-25.
170. Turati F, Galeone C, Rota M, Pelucchi C, Negri E, Bagnardi V, et al. Alcohol and liver cancer: a systematic review and meta-analysis of prospective studies. Annals of Oncology 2014;25(8):1526-35.
171. Turner RM, Davey J, Clarke MJ, Thompson SG, Higgins JP. Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews. International Journal of Epidemiology 2012;41(3):818-27.
172. Van Deusen MA, Abdalla EK, Vauthey JN, Roh MS. Staging classifications for hepatocellular carcinoma. Expert Review of Molecular Diagnostics 2005;5(3):377-83.
173. Van Malenstein H, van Pelt J, Verslype C. Molecular classification of hepatocellular carcinoma anno 2011. European Journal of Cancer 2011;47(12):1789-97.
174. van Valkenhoef G, Lu G, de Brock B, Hillege H, Ades AE, Welton NJ. Automating network meta-analysis. Research Synthesis Methods 2012;3(4):285-99.
175. Von Hahn T, Ciesek S, Wegener G, Plentz RR, Weismuller TJ, Wedemeyer H, et al. Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany. Scandinavian Journal of Gastroenterology 2011;46(9):1092-8.
176. Wan P, Yu X, Xia Q. Operative outcomes of adult living donor liver transplantation and deceased donor liver transplantation: a systematic review and meta-analysis. Liver Transplantation 2014;20(4):425-36.
177. Ware JE. SF-36® health survey update, 2014. www.sf-36.org/tools/sf36.shtml (accessed on 8 October 2014).
178. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology 2008;61(1):64-75.
179. Witjes CD, Karim-Kos HE, Visser O, van den Akker SA, de Vries E, Ijzermans JN, et al. Hepatocellular carcinoma in a low-endemic area: rising incidence and improved survival. European Journal of Gastroenterology and Hepatology 2012;24(4):450-7.
180. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (Clinical Research Ed.) 2008;336(7644):601-5.
181. Wu PC, Fang JW, Lau VK, Lai CL, Lo CK, Lau JY. Classification of hepatocellular carcinoma according to hepatocellular and biliary differentiation markers. Clinical and biological implications. American Journal of Pathology 1996;149(4):1167-75.
182. Xiong JJ, Altaf K, Javed MA, Huang W, Mukherjee R, Mai G, et al. Meta-analysis of laparoscopic vs open liver resection for hepatocellular carcinoma. World Journal of Gastroenterology 2012;18(45):6657-68.
183. Yang Y, Zhang D, Feng N, Chen G, Liu J, Chen G, et al. Increased intake of vegetables, but not fruit, reduces risk for hepatocellular carcinoma: a meta-analysis. Gastroenterology 2014;147(5):1031-42.